MarketResearch announces the publication of its most recently generated research report titled, “Global Biosimilar Monoclonal Antibodies Market by product type, application, and region – Global Forecast to 2026”, which offers a holistic view of the global biosimilar monoclonal antibodies market through systematic segmentation that covers every aspect of the target market. According to the forecast projections, revenue from the global biosimilar monoclonal antibodies market is expected to expand at a moderate CAGR of 19.8% during the forecast period.

According to processed cheese market infographics: Global Automotive Display System Market: Segmental Snapshot

By drug class: Adalimumab segment is estimated to register highest CAGR of over 37.7%, thereby accounting for highest revenue share among the drug class segments.

By application: Oncology segment is estimated to account for highest revenue share among the application segments, and register highest CAGR of over 38.0% over the forecast period.

By region: The market in Europe accounted for highest revenue share in the global biosimilar monoclonal antibodies market in 2016. Revenue from the market in Asia Pacific is expected to expand at a highest CAGR of over 36.9% over the forecast period.

Global Biosimilar Monoclonal Antibodies Market: Competitive Analysis

The research report on the global biosimilar monoclonal antibodies market includes major company profiles such as Pfizer Inc., Novartis AG, Reliance Life Sciences, Biocon, Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, BioXpress Therapeutics, SA., Coherus BioSciences, Inc., Genor BioPharma Co. Ltd., Allergan PLC, Celltrion Healthcare Co. Ltd., and Dr. Reddy’s Laboratories Ltd.

Source of Infographics: Biosimilar Monoclonal Antibodies Market Infographics by MarketResearch